An international study to standardize the detection and quantitation of BCR-ABL transcripts from stabilized peripheral blood preparations by quantitative RT-PCR

Haematologica

Volumn 92, Issue 7, 2007, Pages 970-973

  Müller, Martin C ^a   Saglio, Giuseppe ^b   Lin, Feng ^c   Pfeifer, Heike ^d   Press, Richard D ^e   Tubbs, Raymond R ^f   Paschka, Peter ^a   Gottardi, Enrico ^b   O'Brien, Steven G ^h   Ottmann, Oliver G ^d   Stockinger, Hubertus ^g   Wieczorek, Lothar ^h   Merx, Kirsten ^a   König, Heiko ^a   Schwindel, Uwe ^a   Hehlmann, Rüdiger ^a   Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d GOETHE UNIVERSITY   (Germany)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

^g ROCHE DIAGNOSTICS GMBH   (Germany)

^h NONE

Author keywords

BCR ABL; Chronic myelogenous leukemia; Quantitative PCR; Standardization

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; MESSENGER RNA; RNA;

ADULT; AGED; ARTICLE; BLOOD; COMPARATIVE STUDY; CONTROLLED STUDY; DILUTION; DNA SYNTHESIS; FEASIBILITY STUDY; FEMALE; FREEZING; GENETIC TRANSCRIPTION; HUMAN; LABORATORY; LEUKEMIA; LEUKOCYTE; MACHINE; MALE; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ANALYSIS; RNA EXTRACTION; SENSITIVITY AND SPECIFICITY; SPIKE; STANDARDIZATION; GENETICS; INTERNATIONAL COOPERATION; REPRODUCIBILITY; STANDARD;

FUSION PROTEINS, BCR-ABL; HUMANS; INTERNATIONAL COOPERATION; LEUKEMIA; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 34548793961     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.11172     Document Type: Article

References (13)

1. Lin HJ, Haywood M, Hollinger FB. Application of a commercial kit for detection of PCR products to quantification of human immunodeficiency virus type 1 RNA and proviral DNA. J Clin Microbiol 1996;34:329-33
2. Müller MC, Merx K, Weisser A, Kreil S, Lahaye T, Hehlmann R, et al. Improvement of molecular monitoring of residual disease in leukemias by bedside RNA stabilization. Leukemia 2002;16:2395-9.
3. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors - Review and recommendations for 'harmonizing' current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. International Randomised Study of Interferon versus STI571 (IWS) Study Group. Blood 2006.
4. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82:1929-36.
5. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J, et al. Molecular heterogeneity in complete cytogenetic responders after interferon-a therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group. Blood 2000;95:62-6.
6. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, et al. Frequency of major molecular responses to imatrnib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-32.
7. Müller MC, Gattermann N, Lahaye T, Deininger MW, Berndt A, Fruehauf S, et al. Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon a/ara-C. Leukemia 2003; 17:2392-400.
8. Cortes J, Talpaz M, O'Brien S, Jones D, Luthra R, Shan J, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005;11:3425-32.
9. Gabert J, Beillard E, van dV, Bi W, Grimwade D, Pallisgaard N, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction or fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003; 17:2318-57.
10. Eleaume H, Jabbouri S. Comparison of two standardisation methods in real-time quantitative RT-PCR to follow Staphylococcus aureus genes expression during in vitro growth. J Microbiol Methods 2004;59:363-70.
11. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996;87:1549-55.
12. Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, et al. Molecular monitoring of response to imatinib (Glivec((R)) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission. Leukemia 2003;17:1687-94.
13. Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, et al. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha. Leukemia 2002;16:1579-83.